Policy | 01 February 2026
A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
Growth across inorganic & organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents
Once finalized, cough syrups will no longer be available for over-the-counter sale
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Speakers are: Ch. A. P. Rameswara Rao, National President, BDMAI; Dr. Paidi Yella Reddy, Founder, President & CEO, Sapala Organics; K. V. Rama Gopal, Site Manager & Executive Director, Clariant India; Dr. K. Nagaiah, Chief Scientist, CSIR - Indian Institute of Chemical Technology, Hyderabad; Dr. Satyanarayana Thirunahari, Senior General Manager - Process Safety & Engineering, Laurus Labs; and Yadavendra Shalgaonkar, Assistant General Manager - Tube Sales, Alleima India
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
_LOGO.jpg){kind=logo}
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
The FDA is beginning rulemaking to close the “adequate provision” loophole
Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
Subscribe To Our Newsletter & Stay Updated
